heblaj01
05-19-2006, 08:27 PM
This interview dated 01/03/06 & is titled "Rationale for Use of Biologics in Breast Cancer Treatment: An Expert Interview With Dr. Mark Pegram" is available at http://www.medscape.com/viewarticle/520710
Some interesting points:
-The potential role Fulvestrant (=Faslodex) in preventing ER activation by HER-2 since it suppresses estrogen receptors.
-The phase 1 study of lapatinib showing activity in some Herceptin resistant
patients
-The phase 2 trial of Anastrozole(=Arimidex) with or without Herceptin.
This is the combo that Taffy has just revealed she is on(with fast
successfull initial results on a recurrent primary breast tumour) Although her onc was as surprised as she was, may be he had some interim data from the trial which made him select the treatment.
Dr Pegram again assumes lapatinib might offer an escape to those patients
becoming resistant to the combo. These comments may be used by Tom
in overcoming his mother's predicament if he can convince her onc.
- The ongoing trials involving Herceptin and a VEGF inhibiting drug such
as Avastin
Some interesting points:
-The potential role Fulvestrant (=Faslodex) in preventing ER activation by HER-2 since it suppresses estrogen receptors.
-The phase 1 study of lapatinib showing activity in some Herceptin resistant
patients
-The phase 2 trial of Anastrozole(=Arimidex) with or without Herceptin.
This is the combo that Taffy has just revealed she is on(with fast
successfull initial results on a recurrent primary breast tumour) Although her onc was as surprised as she was, may be he had some interim data from the trial which made him select the treatment.
Dr Pegram again assumes lapatinib might offer an escape to those patients
becoming resistant to the combo. These comments may be used by Tom
in overcoming his mother's predicament if he can convince her onc.
- The ongoing trials involving Herceptin and a VEGF inhibiting drug such
as Avastin